Stéphane Bancel, Moderna CEO (Joel Saget/AFP via Getty Images)

Mod­er­na CEO shares bold new vi­sion: 15 new prod­ucts and 50 new clin­i­cal can­di­dates in five years

If there’s one thing that Mod­er­na CEO Stéphane Ban­cel wants to make abun­dant­ly clear, it’s that his com­pa­ny and its mR­NA tech­nol­o­gy are not a one-hit won­der.

On Wednes­day morn­ing, Mod­er­na an­nounced its in­ten­tions to launch up to 15 new prod­ucts and ad­vance up to 50 mR­NA med­i­cines in­to clin­i­cal tri­als over the next five years — an au­da­cious goal for a biotech best known for its on­ly prod­uct: a Covid-19 vac­cine.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.